Aziyo Biologics announces common stock offering, no amount given

Aziyo Biologics announced that it has commenced an underwritten public offering, subject to market and other conditions, of shares of its common stock. Aziyo intends to use the net proceeds of the offering to expand its product development and clinical research activities, hire additional sales personnel to coincide with product launches and the remainder to fund working capital and other general corporate purposes. Cantor Fitzgerald & Co. is acting as sole book running manager for the proposed offering.